Mirum Pharmaceuticals (MIRM) Raw Materials (2021 - 2026)

Mirum Pharmaceuticals has reported Raw Materials for 6 years, with the latest figure at $2.6 million in Q1 2026.

• For the quarter ending Q1 2026, Raw Materials fell 13.68% year-over-year to $2.6 million; the trailing twelve-month figure through Mar 2026 stood at $2.6 million (down 13.68% YoY), and the FY2025 full-year result was $2.9 million, down 4.36% from the prior year.
• Raw Materials for Q1 2026 stood at $2.6 million, down from $2.9 million in the prior quarter.
• The five-year high for Raw Materials was $3.0 million in Q4 2024, with the low at $444000.0 in Q3 2023.
• Average Raw Materials over 5 years is $2.5 million, with a median of $2.9 million recorded in 2024.
• Year-over-year, Raw Materials soared 528.38% in 2024 and retreated 13.68% in 2026.
• Tracing MIRM's Raw Materials over 5 years: stood at $858000.0 in 2022, then soared by 249.42% to $3.0 million in 2023, then grew by 1.07% to $3.0 million in 2024, then fell by 4.36% to $2.9 million in 2025, then fell by 9.87% to $2.6 million in 2026.
• The last three Raw Materials figures came in at $2.6 million (Q1 2026), $2.9 million (Q4 2025), and $2.9 million (Q3 2025), per Business Quant data.

Peer Comparison